Identification of circulating biomarkers for differentiating patients with papillary thyroid cancers from benign thyroid tumors

J Endocrinol Invest. 2021 Nov;44(11):2375-2386. doi: 10.1007/s40618-021-01543-2. Epub 2021 Mar 1.

Abstract

Background: This study aimed to identify the potential circulating biomarkers of protein, mRNAs, and long non-coding RNAs (lncRNAs) to differentiate the papillary thyroid cancers from benign thyroid tumors.

Methods: The study population of 100 patients was classified into identification (10 patients with papillary thyroid cancers and 10 patients with benign thyroid tumors) and validation groups (45 patients with papillary thyroid cancers and 35 patients with benign thyroid tumors). The Sengenics Immunome Protein Array-combined data mining approach using the Open Targets Platform was used to identify the putative protein biomarkers, and their expression validated using the enzyme-linked immunosorbent assay. Next-generation sequencing by Illumina HiSeq was used for the detection of dysregulated mRNAs and lncRNAs. The website Timer v2.0 helped identify the putative mRNA biomarkers, which were significantly over-expressed in papillary thyroid cancers than in adjacent normal thyroid tissue. The mRNA and lncRNA biomarker expression was validated by a real-time polymerase chain reaction.

Results: Although putative protein and mRNA biomarkers have been identified, their serum expression could not be confirmed in the validation cohorts. In addition, seven lncRNAs (TCONS_00516490, TCONS_00336559, TCONS_00311568, TCONS_00321917, TCONS_00336522, TCONS_00282483, and TCONS_00494326) were identified and validated as significantly downregulated in patients with papillary thyroid cancers compared to those with benign thyroid tumors. These seven lncRNAs showed moderate accuracy based on the area under the curve (AUC = 0.736) of receiver operating characteristic in predicting the occurrence of papillary thyroid cancers.

Conclusions: We identified seven downregulated circulating lncRNAs with the potential for predicting the occurrence of papillary thyroid cancers.

Keywords: Benign thyroid tumors; Biomarker; Circulation; Long non-coding RNAs (lncRNAs); Papillary thyroid cancers; Protein; Thyroid nodule.

MeSH terms

  • Area Under Curve
  • Biomarkers, Tumor / blood
  • Biomarkers, Tumor / classification
  • Cell-Free Nucleic Acids / blood
  • Diagnosis, Differential
  • Down-Regulation
  • Female
  • Gene Expression Profiling / methods
  • Gene Expression Regulation, Neoplastic
  • High-Throughput Nucleotide Sequencing / methods
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Proteins* / blood
  • Neoplasm Proteins* / classification
  • Neoplasms* / blood
  • Neoplasms* / diagnosis
  • Predictive Value of Tests
  • RNA, Long Noncoding / blood*
  • Thyroid Cancer, Papillary* / blood
  • Thyroid Cancer, Papillary* / diagnosis
  • Thyroid Neoplasms* / blood
  • Thyroid Neoplasms* / diagnosis

Substances

  • Biomarkers, Tumor
  • Cell-Free Nucleic Acids
  • Neoplasm Proteins
  • RNA, Long Noncoding